The BAG1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the BAG1 gene has been disrupted to create a loss-of-function model. This genetically engineered cell product enables the functional interrogation of BAG1 in a human colorectal adenocarcinoma background, providing a versatile tool for apoptosis, survival, and signaling studies. The polyclonal format preserves cellular heterogeneity while ensuring robust gene inactivation, suitable for population-level analyses.
The host cell line, HT29, is a well-characterized human colorectal adenocarcinoma model originally isolated from a 44-year-old Caucasian female. These epithelial tumor cells retain key characteristics of intestinal neoplasia, including active proliferative signaling, partial differentiation capacity under specific conditions, and mutation in key oncogenic pathways such as APC and TP53. HT29 cells are widely employed in colorectal cancer research, particularly for studies on epithelial barrier function, chemotherapeutic response, and tumor progression.
BAG1 is a co-chaperone that binds Hsp70 and Hsc70 to regulate protein folding, inhibits apoptosis through Bcl-2 interaction, and activates Raf-1/ERK proliferative signaling. Its expression is induced by heat shock, glucocorticoids, and growth factors via HSF1 and NF-??B. BAG1 also modulates glucocorticoid receptor activity, linking chaperone function to hormonal pathways. Thus, it coordinates a network involving Hsp70, Bcl-2, Raf-1, ERK, and the glucocorticoid receptor to promote survival and growth.
In the HT29 colorectal adenocarcinoma context, BAG1 knockout provides a physiologically relevant system to dissect its role in tumor cell resilience. BAG1 overexpression has been correlated with chemoresistance and poor prognosis in colorectal cancers; therefore, this polyclonal knockout model allows investigation of how loss of BAG1 sensitizes cells to chemotherapeutic agents such as 5-fluorouracil. It also facilitates studies on apoptosis dysregulation and stress adaptation mechanisms intrinsic to intestinal tumor cells, offering insights into therapeutic vulnerabilities.
Researchers can employ this model in diverse experimental workflows, including apoptosis assays (Annexin V staining, caspase activation), cell viability analyses, colony formation assays, and drug sensitivity profiling. Target engagement and signaling pathway dissection can be performed via Western blotting, RT-qPCR, and co-immunoprecipitation to assess BAG1 interactors like Hsp70 and Bcl-2. The polyclonal knockout cells are suitable for investigating chemoresistance mechanisms, validating BAG1 as a drug target, and exploring chaperone biology in cancer. For additional information, please contact Ascent Research.
